Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams says she has lost weight using GLP-1 medication. The drugs help manage blood sugar and promote weight loss, ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...